Novel treatments to help patients with central nervous system disorders


  • 2016-09-20
    - BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research
    Read more »
  • 2016-08-24
    - Update from the Annual General Meeting 2016
    Read more »
  • 2016-04-19
    - US patent on Parkinson’s disease granted
    Read more »
  • 2016-03-15
    - Antibody-based PET imaging of amyloid beta protofibrils in the Alzheimer brain – New findings from Uppsala University in collaboration with BioArctic
    Read more »
  • 2015-09-28
    - Innovative Alzheimer therapy: A new license agreement between BioArctic and Eisai on back-up program to BAN2401
    Read more »



Antibodies targeting toxic proteins



First drug candidate in development for Alzheimer’s disease

Therapeutic Area


CNS disorders

BioArctic enters a strategically important collaboration:

Aiming for a disease modifying treatment for Parkinson’s disease

Gunilla Osswald, CEO: “Our new partner AbbVie has shown a strong commitment to Parkinson’s disease and I am proud that they have chosen to collaborate with BioArctic. I am looking forward to a successful partnership that hopefully will result in a new, innovative disease modifying treatment becoming available to the large number of patients suffering from Parkinson’s disease.” Read more »